CYCLOOXYGENASE 2: UNDERSTANDING THE PATHOPHYSIOLOGICAL ROLE THROUGH GENETICALLY ALTERED MOUSE MODELS

Paloma Martín Sanz1,2, Sonsoles Hortelano2, Lisardo Boscá1,2 and Marta Casado3

1Centro de Investigaciones Biológicas CIB (CSIC), 2Centro Nacional de Investigaciones Cardiovasculares (CNIC). Melchor Fernández Almagro 3, 28029 Madrid (Spain); 3Instituto de Biomedicina de Valencia (CSIC) Jaime Roig 11, 46010 Valencia (Spain)

TABLE OF CONTENTS
1. Abstract
2. Introduction
3. Insight into the physiological roles of COX-2 through genetically altered mice
   3.1. Kidney
   3.2. Gastrointestinal tract
   3.3. Reproduction
   3.4. Brain
   3.5. Cardiovascular system
   3.6. Liver
4. COX-2 in pathological states
   4.1. Inflammation
   4.2. Tumorigenesis
     4.2.1. Gastric and intestinal tumors
     4.2.2. Breast cancer
     4.2.3. Skin carcinogenesis
     4.2.4. Hepatocellular carcinoma (HCC)
5. Summary and Perspectives
6. Acknowledgement
7. References

1. - ABSTRACT

Cyclooxygenase (COX) -1 and -2 catalyze the first step in the biosynthesis of prostanoids. COX-1 is constitutively expressed in many tissues and seems to be involved in the house keeping function of prostanoids. COX-2, the inducible isoform, accounts for the elevated production of prostaglandins in response to various inflammatory stimuli, hormones and growth factors. COX-2 expression has been also associated with cell growth regulation, tissue remodelling and carcinogenesis. More of these characteristics have been elucidate through using COX selective inhibitors. Recent advances in transgenic and gene-targeting approaches allow a sophisticated manipulation of the mouse genome by gene addition, gene deletion or gene modifications. The development of COX-2 genetically altered mice has provided models to elucidate the physiological and pathophysiological roles of this enzyme.

2. - INTRODUCTION

Prostaglandins (PGs) and thromboxanes (TXs), potent bioactive lipid messengers collectively known as prostanoids, are implicated in many physiological processes including platelet aggregation, maintenance of the gastric mucosa integrity and reproduction. In addition to these physiological effects, these prostanoids are regulators of inflammation, fever and pain and play an important role in the pathogenesis of cancer. The biosynthesis of prostanoids occurs in three steps: (i) liberation of arachidonic
acid (AA) from membrane phospholipids by the action of phospholipase enzymes; (ii) the formation of PG endoperoxide H$_2$ (PGH$_2$) from AA mediated by a prostaglandin G/H synthase (EC 1.14.99.1), also known as cyclooxygenase (COX) and (iii) the conversion of PGH$_2$ to a specific prostanoid through the action of specific prostaglandin and thromboxane synthases (figure 1) (1). After prostanoids exited the cells via a carried mediated process, they activate prostanoids-dependent G protein-linked receptors (2) and nuclear receptors of the peroxysome proliferators-activating receptor family (PPARs) (3).

Two isoforms of cyclooxygenase, COX-1 and COX-2, are known. COX-1 is constitutively expressed in many tissues and seems to perform housekeeping functions; by contrast, COX-2 is undetectable in most tissues except placenta, testes, macula densa of the kidney and brain. Nevertheless, COX-2 is rapidly induced in response to various inflammatory stimuli, hormones and growth factors, and has consequently been referred to as the “inducible” isoform (4). However, genetic and pharmacological studies in rodents suggest that both isoforms may be important in maintaining physiological homeostasis and contribute to the inflammatory response and carcinogenesis. Therefore, the designations as housekeeping and/or response gene may not be entirely accurate (5).

COX isoenzymes were found to be approximately 600 amino acids in size in all species. They share 61% primary sequence identity and have similar kinetics properties with minimal differences. It has been suggested that low concentrations of AA (< 2.5 μM) are oxygenated exclusively by COX-2 in intact cells (6). It was proposed that both proteins prefer separate pools of arachidonic acid by using different phospholipases (7). However, recent studies demonstrated that PGs production via COX-2 in activated cells is not controlled by specific coupling between phospholipases and COXs (8).

The structures of COX-1 and COX-2 predict that both enzymes are located in the lumen of nuclear envelope and the endoplasmic reticulum. However, several authors have revealed other localizations of COX-1 (lipid bodies) and COX-2 (caveolin-1-containing vesicles). The physiological significance of the extraluminal localizations is current unknown (9).

The COX-1 promoter region lacks a canonical TATA or CAAT box and is GC rich, features consistent with those of a housekeeping gene. Despite this, COX-1 is inducible in some cells like in endothelia in response to different stimuli (10, 11). On the other hand, there are many consensus cis-elements in the 5’ flanking region regulating the transcription of COX-2 gene, including a TATA box. Among them, CRE, NF-IL6 motifs, NF-kappaB site and the E-box are known to be involved in the regulation of COX-2 gene expression (4). Recently, several authors have shown the importance of NFAT and AP-1 sites in the induction of COX-2 expression upon several stimuli, including phorbol ester PMA/calcium ionophore treatment in tumoral cells (12), vascular endothelial growth factor in vascular endothelial cells (13) or endothelin-1 in rat glomerular mesangial cells (14).

The cyclooxygenases are the pharmacological targets of non-steroidal anti-inflammatory drugs (NSAIDs). Ever since in 1971 Vane first reported the mechanism of action for aspirin-like drugs (15), NSAIDs with varying of isoform specificity have been developed (9). Much our current understanding about the physiological roles of COX-2 has been obtained from studies with NSAIDs. However, it has been identified non-COX-2 targets of NSAID action, reason why the effects observed with these agents may not always reveal the physiological roles of COX isoforms (16-18). To better characterize the physiological and pathological functions of COXs, a number of genetically engineered mouse models have been generated. This review will be focused in the contribution of the transgenic animal models to the study the roles of COX-2 in normal and diseased states.
Both the “gain of function” (transgenesis) and “loss of function” (gene targeting) of individual genes have been utilized for stable modification of the mouse genome, providing powerful experimental systems to study pathophysiology. Transgenesis is mainly achieved by microinjection of the transgenic construct into the pronucleus of 1-cell embryos, which are subsequently implanted into pseudopregnant female mice. In the gene-targeting approach, a gene of interest is replaced with a mutated sequence in embryonic stem cells via homologous recombination. The targeted ES cells are microinjected into blastocysts that are then implanted into receiving females (figure 2) (19).

In spite of the modest number of animal models that constitutively express COX-2, the transgenic mice have provided valuable insight into the COX-2 contribution to tumorigenesis (20-23).

COX knockout models have been profoundly studied. All COX-deficient mice, including the double COX-1/COX-2 knockout mice, are produced in the expected Mendelian ratio, indicating that in mice, embryo implantation and survival in utero does not require fetal PG synthesis (24-27). COX-2 knockout animals lacked the respective normal size message and protein and nor did appear to upregulate the expression of COX-1. Mice deficient in both isoforms are born alive but they die during the first day of life because the ductus arteriosus fails to close after birth. For COX-2-deficient mice that are either wild-type or heterozygous for the COX-1 gene, neonatal mortality is 35 or 79%, respectively. These findings indicate that the PG synthesis required for normal closure of the ductus arteriosus depends primarily on COX-2, although COX-1 provides partial compensation in mice deficient in COX-2.

3. INSIGHT INTO THE PHYSIOLOGICAL ROLES OF COX-2 THROUGH GENETICALLY ALTERED MICE

3.1 Kidney

The kidney is a tissue rich in PG synthesis. Several studies have looked at the importance of COX-2 in renal pathophysiology. In a rat model of glomerulonephritis involving mesangiolysis, the selective inhibition of COX-2 impaired glomerular capillary repair (28). In patients with active lupus nephritis, both renal and systemic COX-2 was upregulated (29). In other models of renal injury such as the remnant kidney, renovascular hypertension and diabetes, increased COX-2 renal expression has also been detected [see (30) for review]. But, it has only been possible to identify a prominent role for COX-2 in both the development and function of the kidney through the characterization of COX-2 knockout model.

One of the most striking findings in the mice lacking the COX-2 gene was the conspicuous abnormalities in kidney structure, mainly consisting of nephron hypoplasia and tubular atrophy. The renal pathology became more severe with age, resulting in end-stage renal disease (25, 26). In the neonatal mouse kidney, the expression of COX-2 increases during the first 4 days after birth and thereafter declines to undetectable levels (31). The initial defects in kidney development in COX-2-null mice are observed at 10 days after birth, with the cortex being abnormally thin with regions of small immature glomeruli and tubular atrophy. In adult COX-2 -/- mice, the nephropathy steps forward tubular dilation, interstitial fibrosis and glomerular sclerosis (32). However, it may possible to overcome this developmental defect by cross-breeding the original COX-2 C57BL/6 deficient mice with a DBA/1 strain (33). The DBA/B6 mice live a full life span with a normal kidney development (34). Recently, Yang et al have studied whether the severity of renal failure in COX-2 deficient mice is also affected by genetic background. Only the male 129/COX-2 deficient mice showed abundant protein casts, dilated tubules and infiltration of inflammatory cells. However,
the presence of small glomeruli in the nephrogenic zone was observed in all studied strains regardless of genetic background and gender. Therefore, the severity of renal failure in COX-2 null mice is influenced by genetic background whereas the incomplete maturation of outer cortical nephrons appears to be independent of genetic background effects (35).

In addition to its role in postnatal renal development, COX-2 also contributes to modulate specific functions in adult kidney. In the renal cortex, COX-2 expression is localized to the macula densa and the adjacent thick ascending limb, in where COX-2 expression is induced by reductions in the NaCl concentrations (36). Thanks to COX-2 deficient mice, it has been proposed a role of COX-2 in the stimulation of renin production and secretion following reduced dietary sodium (37) or the inhibition of angiotensin-converting enzyme (38). Under conditions where renin expression and activity are induced in wild-type mice, the kidneys from COX-2 deficient mice do not respond to these stimuli. Therefore, COX-2 appears to be the isoform primarily responsible for maintaining renal homeostatic functions involved in the regulation of salt resorption, fluid volume and blood pressure.

3.2 Gastrointestinal Tract

PG synthesis can be demonstrated to occur in every part of the gastrointestinal tract where they have a cytoprotective role. In rat tissues, the PGs levels were greatest in gastric muscle and forestomach, followed by gastric mucosa, colon, rectum, ileum, cecum, duodenum, jejunum and esophagus. The mechanism of the cytoprotective action of PGs is complex and involves the decrease of secretion of gastric acid, the direct vasodilator action on the gastric mucose and the stimulation of viscous mucus (9).

Initially, it has been proposed that PG synthesis dependent on COX-1 is important for maintenance of mucosal integrity. Thus, the inhibition of COX-1 was thought responsible for ulcerative effects of NSAIDs. The reduced gastric toxicity of COX-2 selective inhibition further supported this hypothesis (39). However, the COX-1 deficient mice did not spontaneously develop stomach ulcers (24). Moreover, COX-2 null mice were more susceptible to colonic injury with dextran sodium sulfate than wild-type mice (40). Similarly, SC-560, a selective COX-1 inhibitor, or celecoxib, a selective COX-2 inhibitor, administrated to rats, produced gastric damage. Thus, genetic and pharmacological studies in rodents suggest that the combined inhibition of both COX-1 and COX-2 is required to produce gastric damage.

3.3 Reproduction

Whereas COX-2 null male mice showed normal fertility, the deletion of the COX-2 gene in female mice resulted in infertility with defects in ovulation, implantation and decidualization. Lim et al (41) observed that few eggs were recovered following superovulation of COX-2 null mice, and only 2% of the released eggs were fertilized. In preovulatory follicles, COX-2 expression is normally induced by pituitary gonadotropins, indicating that COX-2 accounted for increased ovarian PG production following the luteinizing hormone surge (42). The decrease of PGE2 synthesis in the ovaries of COX-2 knockout mice disrupts cumulus activation, stigmata formation and ovulation, which can be restored by treatment with PGE2 (42). The process of ovulation becomes extremely poor in COX-2 or EP2-null mice, suggesting an important role of COX-2-derived PGE2 in this process. Moreover, ovulation in younger COX-2 knock out mice that responded to gonadotropins for superovulation, was superior compared to that in adult COX-2 deficient mice, suggesting that ovulatory process becomes more dependent on COX-2-
derived PGE$_2$ effects with aging (43). However, follicular growth in vivo and oocyte maturation in vivo or in vitro are, apparently, normal in both knock out models. Furthermore, subsequent in vitro fertilization of oocytes and their development in vitro proceed normally to blastocyst stage. In addition, many of these blastocysts showed signs of zona hatching, suggesting that COX-2-derived PGE$_2$ of maternal origin is not required for oocyte maturation, fertilization or preimplantation development (43).

COX-2 and PGI synthase (PGIS) coexist at the implantation site, suggesting the availability of PGI$_2$ directly to uterine cells. Concerning a target receptor for PGI$_2$ in the uterus, PPAR$\delta$ was shown highly colocalized at similar regions of the implantation sites with COX-2 and PGIS; the expression of other known receptors activated by PGI$_2$, IP and PPAR$\alpha$, was very low to undetectable. The functionality of PPAR$\delta$ as a PGI$_2$ receptor was further validated in vivo, using COX-2-deficient mice as a model. Administration of cPGI (carbaprostacyclin, PGI$_2$ agonist) or L-165041 (a selective PPAR$\delta$ agonist) improved implantation and decidualization defects in COX-2(-/-) mice. This effect is further potentiated by RXR agonists (44). Interestingly, coadministration of cPGI with PGE$_2$ markedly improved embryonic and decidual growth in COX-2 deficient mice (44).

In conclusion, the study of COX-2 deficient mice has established the essential role of COX-2 in female reproductive process. The fact that COX-2-derived PGE$_2$ participates in ovulation and fertilization via the EP2 receptor subtype (45), whereas COX-2-derived PGI$_2$ is important for the initial stages of implantation and subsequent decidualization, via the nuclear receptor PPAR$\delta$ in the uterus, illustrate a fascinating distinction as to how specific PGs elicit unique physiological function through utilization of differential signaling pathways.

3.4 Brain

Brain (neurons of hippocampus, cerebral cortex, amygdale and hypothalamus) and spinal cord express relatively high basal levels of COX-2, which is though to play a role in fundamental brain functions, such as synaptic activity, synaptic remodeling, memory consolidation and functional hyperemia (46, 47). COX-2 expression is rapidly and transiently upregulated in neurons microglia and astrocytes in response to excitatory synaptic transmission mediated by NMDA receptor activation (46) or a variety of neurotoxic stimuli (48-50).

COX-2 deficient mice show increased resistance to focal ischemic injury induced by transient middle cerebral artery occlusion or by NMDA-induced neurotoxicity (51). The lower degree of hippocampal neuronal injury in COX-2 deficient mice agreed with an attenuation of DNA fragmentation in the hippocampus, event reproduced by nimesulide treatment (52). The inhibition of COX-2 protein expression protected the dopaminergic neurons in substantia nigra pars compacta, suggesting a potential therapeutic implication (53). These results show that neuronal COX-2 is likely to function in promoting neuronal injury.

The injury conditions indicated above involve an activation of the NF-kappaB pathway. Rao et al (54) have recently showed that NF-kappaB DNA binding activity was significantly decreased in COX-2 null mice compared to wild-type mice, possibly due to a decrease in brain protein levels of p65, phosphorylated-p65 and phosphorylated-Ikappa-B alpha levels. These results suggest a reciprocal coupling between NF-kappaB and COX-2.
It has also been developed a C57BL6/J inbred strain transgenic mouse model in which human COX-2 was selectively overexpressed in neurons of the central nervous system using the Thy-1 promoter (HCOX-2 mice). This promoter has a high level of neuron-specific expression that begins in the second postnatal week (55). HCOX-2 mice develop cognitive deficits in an age-dependent manner, associated with a parallel age-dependent increase in neuronal apoptosis and astrocytic activation (22). HCOX-2 mice have been also tested in a model of transient focal ischemia. A significant increase in infarct volume was observed after middle cerebral artery occlusion, supporting previous mentioned studies in COX-2 null mice (56).

3.5 Cardiovascular System

COX-1 is highly expressed in the normal vascular tissues, whereas COX-2 expression is elevated in proliferating vascular cells, for example angiogenic microvessels, atherosclerotic lesions and inflamed tissues (57). It has also been reported the expression of COX-2 in ischemic human myocardium and in dilated cardiomyopathy, but not in normal cardiomyocytes (58). All these findings seem indicate a detrimental role of COX-2 in cardiovascular homeostasis.

However, there are also evidences suggesting physiologically important protective actions of COX-2. In contrast of Wong’s work, 50% of COX-2 null mice developed a diffuse myocardial fibrosis, suggesting that COX-2 deficiency might be involved in cardiomyopathy (26). COX-2 protects cardiomyocytes against oxidative stress (59) and the increase in COX-2 activity associated to ischemic preconditioning mediates the protective effects of the late phase of preconditioning against both myocardial stunning and myocardial infarction (60). Furthermore, pharmacological COX-2 inhibition improved cardiac function after myocardial infarction in the mouse (61).

In addition, the clinical experience accumulated with COX-2 inhibitors in the past three years also suggests the protective effects of COX-2 in patients with cardiovascular disease (62). Thus, the Vioxx Gastrointestinal Outcomes Research clinical trial showed a fivefold increase in myocardial infarction in patients treated with rofecoxib compared with the traditional NSAID naproxen (63). The COX-2 inhibitors reduce the production of prostacyclin (PGI₂) but not that of COX-1-derived thromboxane A₂ (TXA₂). Thus, the effects of TXA₂ are exacerbated during extended therapy with specific COX-2 inhibitors (COXIBs), potentially predisposing patients to heart attack and stroke (64, 65).

At sight of all these data, we can conclude that the actions of prostanoids in pathological situations are varied and complex. Some appear to be beneficial, countering the worst effects of disease, whereas others contribute to its further development. This complexity might derive from the fact that different cell types in the heart, e.g., myocytes, fibroblasts and endothelial cells produce different prostanoids profiles. The effect of COX-2 induction or inhibition will depend on the cell in which it is expressed, the prostanoids produced, and the ability of surrounding cells to respond to these prostanoids. The outcome of COX-2 activity and subsequent prostanoid signaling will therefore be an exquisite and highly dynamic balance among these different and often conflicting signals. Disturbance of this delicate balance may determine whether prostanoid signals have beneficial or deleterious effects during the development of important cardiovascular pathologies; a comprehensive understanding of prostanoid actions and functions during these disease processes are required. In that sense, in our group we have generated a transgenic mouse that constitutively expresses COX-2 in cardiomyocytes. With this model we try to know with better precision the pathophysiologic role of COX-2 in the heart.
3.6 Liver

There are many studies that reported COX-2 expression and induction in whole liver homogenates, mainly in different experimental models of liver pathology (66, 67). The expression and induction of COX-2 in Kupffer cells is well documented. COX-2 expression in these cells was increased by different stimuli such as hyperosmolarity (68), alcohol (66), proinflammatory cytokines and LPS (69, 70) both \textit{in vitro} and \textit{in vivo}. However, the contribution of hepatocytes to liver PGs synthesis is more controversial. Johnston et al (71) using ricin-purified hepatocytes to completely eliminate Kupffer and endothelial cells, demonstrated that hepatocytes do not produce COX products even with conditions favoring lipid peroxidation.

Hepatocytes respond to most of the stimuli that positively regulate COX-2 expression in other cells, including LPS, IL-1 beta and TNF-alpha. Interestingly, fetal hepatocytes, which exhibit a liver phenotype distinct from the adult counterpart, were able to express COX-2 upon challenge with LPS and pro-inflammatory cytokines (72). Regarding the mechanism responsible for the suppression of COX-2 inducibility in adult hepatocytes, our results have shown that the activity of the COX-2 promoter declined rapidly after birth paralleling the expression of C/EBP-alpha in neonatal hepatocytes (73). Attractively, partial hepatectomy (PH) favors hepatocyte de-differentiation and triggers a rapid regenerative response in the remnant tissue to reinstate the organ function and the cell number. In this vein, it has been shown that COX-2 is expressed in liver at 16 hours after PH (74). Studies of PH through animal models have recently been reviewed in greater detail elsewhere (75).

Studies in the physiological significance of COX-2 expression after PH showed alterations in various parameters of cell cycle progression in animals pretreated with NS398, a selective COX-2 inhibitor, and in COX-2 deficient mice (74, 76). In the genetic model of COX-2 targeting in mice, our own data demonstrated that the lack of PG synthesis results in a delay in the first cycle of hepatocyte proliferation. However, measurement of overall liver mass recovery one week after PH failed to show significant differences between control and COX-2 deficient animals, which suggest that other growth-promoting mechanisms play a more significant role in the latter phase of the regeneration process (figure 3).

In conclusion, most of the results indicate that COX-2 expression in hepatocytes is restricted to those situations in which dedifferentiation or proliferation occurs, suggesting an important role of PGs in the onset of liver pathologies including hepatocellular carcinoma (HCC) (77).

4. COX-2 IN PATHOLOGICAL STATES

4.1 Inflammation

The initial studies for characterizing the COX-2 contribution to the development of inflammation involved the induction of edema by 12-o-tetradecanoylphorbol-13-cetate (TPA), a potent inducer of COX-2 expression, applied topically to the ear of COX-2 knockout mice (78). Surprisingly, the level of edema induced by TPA was not significantly different between wild-type and COX-2 deficient mice.

Sepsis is a systemic inflammatory response to a blood-borne infection that is associated with an extremely high rate of morbidity and mortality. COX-2 deficient mice are resistant to many of the detrimental consequences of endotoxemia such as the leukocyte infiltration into critical organs (kidneys and lung), the induction of nitric oxide synthase 2 and heme oxygenase-1 or activation of NF-kappaB pathway (79). These beneficial effects occur in part by a compensatory increase in IL-10 that
counterbalances the pro-inflammatory host response to endotoxemia. Thus, COX-2 is a critical component of the lethal response associated with endotoxemia in mice.

Comparing the results observed in endotoxemic COX-2 null mice or mice treated with TPA, it has been deduced that the importance of COX-2 in an inflammatory response may also depend on the initiating stimulus.

4.2 Tumorigenesis

The role of COX-2 and the PGs resulting from its enzymatic activity in modulating cell growth and the development of neoplasia is well established mainly in colon cancer (80). Overexpression of COX-2 promotes tumorigenesis in colon cells and in some models of transgenic mice, whereas inhibition of COX-2 by NSAIDs and COXIBs is anti-neoplastic although COX independent pathways could also be involved in the antiproliferative effects of NSAIDs (81, 82). In fact, at least five mechanisms by which COX-2 contributes to tumorigenesis and malignant phenotype have been proposed: inhibition of apoptosis mediated by Bcl-2, Par-4 and protein kinase B (Akt/PKB) signalling (83, 84), increased angiogenesis through the production of VEGF and PGs (85) increased invasiveness via activation of metalloproteinases (86) and conversion of procarcinogens to carcinogens (87).

Is COX-2 overexpression sufficient to induce tumorigenesis? Several COX-2 genetically altered mice models have been developed for answering this question.

4.2.1. Gastric and Intestinal Tumors

In 1996 Oshima and collaborators provided definitive evidence that COX-2 is required for intestinal tumorigenesis. In a mouse model of human familial adenomatous polyposis, intestinal tumor development is reduced by the genetic deficiency of COX-2 (88). However, by utilizing COX-1 deficient mice, Lagenbach et al showed that deletion of COX-1 gene also attenuated polyp formation (89). Therefore, both COX-1 and COX-2 may be important in intestinal tumorigenesis.

Accumulating evidence shows that COX-2 expression is also induced in the gastric cancer tissues (90). Among various prostanoids, PGE₂ appears to be the responsible for cancer development (91). To investigate the role of COX-2 in gastric tumorigenesis, transgenic mice simultaneously expressing COX-2 and microsomal PGE₂ synthase was generated. The specific gastric epithelial cell expression was obtained by using the cytokeratin 19 (K19) promoter (92). The transgenic mice developed metaplasia, hyperplasia and tumors in the glandular stomach with heavy macrophage infiltrations (20).

4.2.2. Breast Cancer

The question of whether COX-2 overexpression is sufficient to induce tumorigenesis was addressed by human COX-2 overexpression in the mammary glands of CD1 mice using the mouse mammary tumor virus promoter (MMTV). This promoter is highly expressed in the mammary epithelium during pregnancy and lactation (93). Female virgin COX-2 transgenic mice showed precocious alveolar differentiation and enhanced expression of beta casein gene. Multiparous females exhibited exaggerated incidence of focal mammary gland hyperplasia, dysplasia, and transformation into metastatic tumors. The reduced levels of Bax and Bcl-XL proteins and the decrease of Bcl-2 levels in COX-2 induced tumors suggested that decreased apoptosis of mammary epithelial cells contribute to tumorigenesis (21). Moreover, PGE₂ stimulated the expression of angiogenic regulatory genes in mammary tumor cells isolated from MMTV-COX-2 transgenic mice (94). These results define, in part, the molecular
basis of how COX-2 transforms the mammary gland into a tumorigenic state. Recently, it has been showed that PGE_2 stimulates angiogenesis via the EP_2 receptor, mediating VEGF upregulation via the cAMP/PKA pathway (95).

Narko and collaborators have been characterized the MMTV-COX-2 FVB/N transgenic mice (96). FVB/N is an inbred strain which has robust reproductive characteristics and is susceptible to breast cancer formation. MMTV-COX-2 FVB/N transgenic mice had high incidence of mammary tumors similar to CD1 mice suggesting that observed phenotype is due to COX-2 expression and not an aberrant effect of site of integration.

4.2.3. Skin Carcinogenesis

Recent transgenic overexpression studies in which COX-2 was targeted to the skin of transgenic mice support the notion that upregulated expression of COX-2, perhaps induced by carcinogenic stimuli or other tumor promoters, is an important contributor of tumorigenesis. In mice and humans, deregulated expression of COX-2, but not of COX-1, is characteristic of epithelial tumors, including squamous cell carcinomas of skin (97). To explore the function of COX-2 in epidermis, a keratin 5 promoter was used to direct COX-2 expression to basal epidermal cells and the pilosebaceous unit of mouse skin (K5-COX-2) (23). The transgenic animals did not exhibit symptoms of inflammation, indicating that COX-2 expression alone is not sufficient to initiate an inflammatory response in mouse skin.

K5-COX-2 mice morphogenesis of pelage and the number of hair follicles was reduced probably due to an impairment of hair follicle induction. Furthermore, transgenic mice developed alopecia (98). Aberrant COX-2 expression in basal gland epithelial cells correlated with sebaceous gland hyperplasia and increase of epicutaneous sebum levels (23). The K5-COX-2 transgenic mice did not develop skin tumors spontaneously but did so after a single application of an initiating dose of the carcinogen 7, 12-dimethyl-benz[a]anthracene (DMBA) (99). Thus, overexpression of COX-2 targeted to basal keratinocytes contributes to skin-tumor promotion and progression by establishing a preneoplastic skin phenotype. Nevertheless, these results are in controversy with other authors who have shown that the COX-2 deficiency altered epidermal differentiation and reduced mouse skin tumorigenesis (100).

COX-2 null mice have been also used to evaluate the involvement of COX-2 activity in sulfur mustard induced skin toxicity (101). Sulfur mustard (SM) is a potent vesicant and chemical warfare agent that induces tissue damage involving an inflammatory response (102). The relatively low susceptibility of COX-2 null mice to SM, expressed by reduced ear swelling and absence of epidermal ulceration and encrustation, demonstrates that COX-2 actively participates in the acute phase of inflammation caused by SM.

4.2.4. Hepatocellular Carcinoma

Although the pathogenesis of hepatocellular carcinoma (HCC) remains poorly defined, several studies indicate that this is a multifactorial, multistep process involving the alteration of oncogenes, tumor suppressor genes and host chromosomes, as well as an abnormal expression of growth factors and COX-2 on the whole resulting in a reduced apoptosis.

COX-2 expression in human hepatoma cell lines is well documented. COX-2 is expressed in 75% of different hepatoma cell lines studied, for example, HepG2, HuH7, Hep3B, Sk-hep 1 and SMMC-7721 cells (103-107). Failure of apoptosis is an important event in tumor progression and resistance to cytotoxic therapy (108). Treatment of these cells with COX-2 inhibitors,
such as aspirin, nimesulide, NS-398 or celecoxib, inhibited cell growth, invasiveness and proliferation at the time that induced apoptosis. With respect to the mechanisms involved, it has been proposed that COX-2 promotes hepatocellular carcinoma progression through Akt activation (109). Aspirin and NS-398 inhibit HGF-induced invasiveness in HepG2 cells through ERK1/2 activation (106) and apoptosis induced by COX-2 inhibitors was correlated with the activation of caspase-9, 3 and 6 (103).

However, the in vitro anti-HCC effect of NSAIDs and COXIBs needs to be confirmed in animal models in vivo. In this sense, we have developed, as an initial approach, an in vivo model to deliver the human COX-2 gene to the mouse liver via hydrodynamics-based transient transfection as described previously (110). Through this model, it has been demonstrated that PGs produced by COX-2 expression protected the liver against Fas-mediated apoptosis. The mechanism involves potent inhibition of caspases 3 and 9 (unpublished data). Moreover, our group is working to develop a transgenic mice model that constitutively express COX-2 in hepatocytes to confirm the involvement of COX-2 in HCC and the anti-tumoral effects of the COX-2 inhibitors.

5. SUMMARY AND PERSPECTIVES

Generation and characterization of COX-2 genetically altered mouse models, as reviewed in this article, have greatly facilitated identification of the mechanisms by which the COX-2 contributed to normal physiology and various pathological states (table 1). However, caution should be exercised when we used this powerful technology because, for example, differences in genetic background of different mouse strains can affect transgene expression and phenotype due to strain specific modifiers of expression.

Nevertheless, future refinement and generation of new COX-transgenic models, including the generation of conditional gene-targeted mouse models that may allow for the temporal and spatial control of gene expression, would be a tremendous advantage in exploring the genetic basis of COX-2 function and dysfunction. Furthermore, it can be anticipated that new approaches will appear which permit control not only the COX-2 activity, spatially and temporally, but also quantitatively, which is known to be central to many biological process.

6 ACKNOWLEDGEMENTS

This work was supported by grants from Instituto de Salud Carlos III (Red de Centros C03/01), Generalitat Valenciana (GRUPOS03/072), Ministerio de Educación y Ciencia (SAF2004-00957) and Comunidad de Madrid (CAM2004-GR/SAL/0388).

7. REFERENCES


2). Taketo: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).


Expression of cyclooxygenase isozymes during morphogenesis and cycling of pelage hair follicles in mouse skin: precocious onset of the first catagen phase and alopecia upon cyclooxygenase-2 overexpression.


Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin.


Leng, J., C. Han, A. J. Demetris, G. K. Michalopoulos & T. Wu: Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.

Liu, F., Y. Song & D. Liu: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA.

Key words: cyclooxygenase, prostanoids, genetically altered animal models

Send correspondence: Marta Casado; Instituto de Biomedicina de Valencia (CSIC) Jaime Roig 11, 46010 Valencia (Spain).

Telf: +34963393778; Fax: +34963690800; Email: mcasado@ibv.csic.es
FIGURE LEGENDS

Figure 1. The arachidonic acid cascade: role of the cyclooxygenase in the production of the constitutive and inducible eicosanoids (prostaglandins, thromboxanes and leukotrienes). The primary function of each eicosanoid is shown.
Figure 2. Schematic diagrams of transgenic (panel A) or gene-targeting (panel B) approaches for stable modification of the mouse genome.

Panel A:
- Vasectomized male mouse and superovulated female mouse cross
- Collection of fertilized eggs
- Micro-injection
- Reimplantation into pseudopregnant female mouse
- Birth of transgenic offspring

Panel B:
- Cross between 129 agouti and C57Bl/6j mice
- Embryonic stem cells (ES) generation
- Trophoblast blastocyst (3.5 jpc) injection
- Selection of resistant clones (RH)
- Chimeric mice production
**Figure 3.** Physiological significance of COX-2 expression after PH showed alterations in various parameters of cell cycle progression: COX-2 deficient mice (KO) mice exhibited an impaired incorporation of \(^{3}\)H)thymidine into hepatocyte nuclei at 48h after PH (radioactive nuclei appear yellow) and, in agreement with these results, the levels of PCNA, a marker of S phase, were 65% lower in the KO mice compared with the wild-type littermates.
### Table 1. Characteristics of COX-2 genetically altered mouse.

<table>
<thead>
<tr>
<th>Pathophysiological Process</th>
<th>Transgenic mice</th>
<th>COX-2 deficient mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonatal mortality</td>
<td></td>
<td>Increased (25,26,27)</td>
</tr>
<tr>
<td>Adult mortality</td>
<td></td>
<td>Increased (25)</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td></td>
<td>Increased (27)</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td></td>
<td>Impaired (25,26,32)</td>
</tr>
<tr>
<td>Postnatal kidney development</td>
<td></td>
<td>Altered (36,37,38)</td>
</tr>
<tr>
<td>Renal homeostasis functions</td>
<td></td>
<td>Impaired (41,42)</td>
</tr>
<tr>
<td>Mucosal integrity</td>
<td></td>
<td>Normal (24)</td>
</tr>
<tr>
<td>Neuronal injury</td>
<td>Increased (22)</td>
<td>Increased (51,52,53)</td>
</tr>
<tr>
<td>Cognitive deficits</td>
<td>Age-dependent (56)</td>
<td></td>
</tr>
<tr>
<td>Cardiac fibrosis</td>
<td></td>
<td>Increased (26)</td>
</tr>
<tr>
<td>Liver regeneration</td>
<td></td>
<td>Altered (74)</td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
<td>Altered (79)</td>
</tr>
<tr>
<td>Intestinal tumorigenesis</td>
<td>Increased (20)</td>
<td>Decreased (88)</td>
</tr>
<tr>
<td>Mammary gland</td>
<td>Metastatic tumors (21,96)</td>
<td></td>
</tr>
<tr>
<td>Morphogenesis and number of hair follicles</td>
<td>Altered (alopecia) (98)</td>
<td></td>
</tr>
<tr>
<td>Sebaceous glands</td>
<td>Hyperplasia (23)</td>
<td></td>
</tr>
<tr>
<td>Skin tumors</td>
<td>Increased in response of carcinogens (99)</td>
<td>Reduced (101,102)</td>
</tr>
<tr>
<td>Liver apoptosis</td>
<td></td>
<td>Protected (unpublished data)</td>
</tr>
</tbody>
</table>